Chikungunya Virus E1 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-13438
Key Product Details
Species Reactivity
Virus
Applications
Immunocytochemistry/ Immunofluorescence, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Recombinant protein encompassing a sequence within the center region of Chikungunya Virus E1 (Chikungunya virus (strain S27-African prototype)). The exact sequence is proprietary.
Reactivity Notes
Chikungunya Virus
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Description
Centrifuge briefly prior to opening.
Scientific Data Images for Chikungunya Virus E1 Antibody
Western Blot: Chikungunya Virus E1 Antibody [NBP3-13438] -
Western Blot: Chikungunya Virus E1 Antibody [NBP3-13438] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with Chikungunya Virus E1 antibody (NBP3-13438) diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.
Western Blot: Chikungunya Virus E1 Antibody [NBP3-13438] -
Western Blot: Chikungunya Virus E1 Antibody [NBP3-13438] - Chikungunya viral lysate (0.5 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with Chikungunya virus E1 antibody diluted at 1:50000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.
ICC/IF-Chikungunya Virus E1 Antibody [NBP3-13438] -
ICC/IF-Chikungunya Virus E1 Antibody [NBP3-13438] -Analysis of mock and Chikungunya virus-infected cells using Chikungunya virus nsP2 antibody [HL1488].Sample: Chikungunya virus non-infected and infected cells slide.Green: Chikungunya virus nsP2 antibody [HL1488] diluted at 1:100.Blue: Fluoroshield with DAPI.Applications for Chikungunya Virus E1 Antibody
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
-Assay dependent
Western Blot
1:5000
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Formulation
PBS, 20% Glycerol
Preservative
0.025% Proclin 300
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: Chikungunya Virus E1
Although analysis suggests CHIKV originated in Africa over 500 years ago, first infections weren't reported until the 1950s (1-3). CHIKV has evolved three distinct genotypes, or strains, based on location, termed West African (WA), East/Central/Southern African (ECSA), and Asian (2-3). The WA strain has been most closely associated with enzootic transmission whereas the ECSA strain contributes more to urban epidemics (2). Nonhuman primates are the primary reservoir for the viral host with transmission occurring via mosquitos biting and infecting humans (1-3). Upon acute infection, the virus replicates in cells including fibroblasts and macrophages resulting in innate immune response in infected tissues characterized by infiltrating cells like macrophages, monocytes, natural killer (NK) cells, and lymphocytes (2,3). Infection results in increased production of proinflammatory cytokines such as interferon alpha (IFN-alpha) and interleukin 6 (IL-6), chemokines, and growth factors (2,3). Physical manifestations of infection are high fever, polyarthralgia, headache, arthritis, and rash (1-3). CHIKV symptoms can be confused with other infections like those from dengue fever and Zika virus (1-3). There are no specific antivirals or vaccines for CHIKV, but rather symptoms are treated with antipyretics and non-steroidal anti-inflammatory drugs (NSAIDs) (2,3). While in vitro culture models and in vivo rodent and non-human primate models have been used to study CHIKV pathogenesis and advance our knowledge of the disease, the specific cellular mechanisms are not fully understood (3).
References
1. Vu DM, Jungkind D, Angelle Desiree LaBeaud. Chikungunya Virus. Clin Lab Med. 2017;37(2):371-382. https://doi.org/10.1016/j.cll.2017.01.008
2. Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737-749. https://doi.org/10.1172/JCI84417
3. Ganesan VK, Duan B, Reid SP. Chikungunya Virus: Pathophysiology, Mechanism, and Modeling. Viruses. 2017;9(12):368. Published 2017 Dec 1. https://doi.org/10.3390/v9120368
Long Name
Chikungunya Virus Envelope 1
Alternate Names
CHICKV E1, CHIKV-E1
Additional Chikungunya Virus E1 Products
Product Documents for Chikungunya Virus E1 Antibody
Product Specific Notices for Chikungunya Virus E1 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...